Key Takeaways
- • IM8, co-founded by David Beckham and health-science firm Prenetics Global Ltd., secured $1 billion in growth financing from General Catalyst's Customer Value Fund on July 14, 2026.
- • General Catalyst's Customer Value Fund will finance up to 70% of IM8's marketing spend and receive a capped share of income generated from the company's operations.
- • IM8 has achieved a $200 million run rate within 18 months of operations, demonstrating rapid revenue growth in the premium daily nutrition and supplement category.
- • The financing structure represents a non-equity investment model, with General Catalyst providing capital based on marketing ROI and revenue sharing rather than traditional venture equity stakes.
- • The deal positions IM8 to accelerate global marketing expansion across major markets while maintaining capital efficiency through outcome-based financing.
Summary
IM8, the premium daily nutrition and supplement company co-founded by former footballer David Beckham and health-science firm Prenetics Global Ltd., has secured $1 billion in growth financing from venture capital firm General Catalyst's Customer Value Fund. The announcement, made on July 14, 2026, represents a significant capital injection for the rapidly scaling wellness brand.
The financing structure diverges from traditional venture equity investments. General Catalyst's Customer Value Fund will finance up to 70% of IM8's marketing expenditures and receive a capped share of income generated by the company, according to Bloomberg News. This approach aligns the investor's returns directly with marketing effectiveness and revenue generation rather than equity ownership, creating an outcome-based partnership model.
IM8's rapid trajectory underscores the investment appeal. The company has achieved a $200 million run rate within 18 months of founding, demonstrating substantial market traction in the longevity and supplement category. The fresh capital injection is designated to accelerate IM8's global marketing efforts across major markets, leveraging General Catalyst's strategic capital to drive customer acquisition at scale.
General Catalyst's Customer Value Fund specializes in this type of capital provision, offering growth financing tied to customer and revenue metrics rather than equity dilution. For IM8, this structure enables aggressive market expansion while preserving equity ownership and maintaining alignment between capital deployment and measurable business outcomes. The deal reflects the broader venture ecosystem's evolution toward alternative financing mechanisms for high-growth consumer and health-tech companies demonstrating strong unit economics.
The financing structure diverges from traditional venture equity investments. General Catalyst's Customer Value Fund will finance up to 70% of IM8's marketing expenditures and receive a capped share of income generated by the company, according to Bloomberg News. This approach aligns the investor's returns directly with marketing effectiveness and revenue generation rather than equity ownership, creating an outcome-based partnership model.
IM8's rapid trajectory underscores the investment appeal. The company has achieved a $200 million run rate within 18 months of founding, demonstrating substantial market traction in the longevity and supplement category. The fresh capital injection is designated to accelerate IM8's global marketing efforts across major markets, leveraging General Catalyst's strategic capital to drive customer acquisition at scale.
General Catalyst's Customer Value Fund specializes in this type of capital provision, offering growth financing tied to customer and revenue metrics rather than equity dilution. For IM8, this structure enables aggressive market expansion while preserving equity ownership and maintaining alignment between capital deployment and measurable business outcomes. The deal reflects the broader venture ecosystem's evolution toward alternative financing mechanisms for high-growth consumer and health-tech companies demonstrating strong unit economics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.